Screener
Crinetics Pharmaceuticals CRNX Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | As of March 31, 2026 / Amortized Cost | As of March 31, 2026 / Gross Unrealized Gains | As of March 31, 2026 / Gross Unrealized Losses | As of March 31, 2026 / Fair Market Value | As of December 31, 2025 / Amortized Cost | As of December 31, 2025 / Gross Unrealized Gains | As of December 31, 2025 / Gross Unrealized Losses | As of December 31, 2025 / Fair Market Value |
|---|---|---|---|---|---|---|---|---|
| Available-for-sale investment securities: | ||||||||
| U.S. government obligations | $562,634 | $279 | $(833) | $562,080 | $369,652 | $860 | — | $370,512 |
| Agency obligations | 64,499 | 2 | (205) | 64,296 | 43,997 | 1 | (29) | 43,969 |
| Corporate debt securities | 550,943 | 378 | (732) | 550,589 | 510,668 | 1,215 | (11) | 511,872 |
| Total | $1,178,076 | $659 | $(1,770) | $1,176,965 | $924,317 | $2,076 | $(40) | $926,353 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's unrealized losses on investments (before tax)?
- Crinetics Pharmaceuticals (CRNX) reported unrealized losses on investments (before tax) of $1.77M in Q1 2026.
Ask your AI about Crinetics Pharmaceuticals's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude